Govt issues alert on Nimesulide

  • 13 Apr 2024

On April 2024, the Indian Pharmacopoeia Commission (IPC) issued a drug safety alert regarding Nimesulide, an anti-inflammatory drug, citing potential skin rashes as an adverse effect.

Key Points

  • Nimesulide Overview: Nimesulide, classified as a Non-steroidal anti-inflammatory drug (NSAID), is prescribed to alleviate pain, inflammation, and swelling associated with various conditions, including fever, menstrual cramps, and osteoarthritis.
  • Identifying Allergic Reactions: Patients with known drug allergies or underlying health issues, such as kidney or liver disease, should inform their doctors.
  • Administration Guidelines: Patients are advised to follow prescribed dosages, take the medication with food, and discontinue its use as per the doctor's instructions.
  • Contraindications: Individuals with blood coagulation issues, children, pregnant or nursing women, and those with a history of stomach ulcers, heart failure, or liver and kidney conditions should avoid Nimesulide.
  • Monitoring and Response: Patients should remain vigilant for any adverse reactions, particularly within the initial days of usage.
  • Historical Context: Nimesulide faced bans in several countries, including Switzerland, Spain, and the US, due to safety concerns.
  • In India, its usage for adults persists but is not recommended for children since 2011.